Dabigatran PBS listing ‘imminent’

An announcement is expected within days on the long-delayed PBS listing of the novel oral anticoagulant dabigatran (Pradaxa) for patients with non-valvular atrial fibrillation, manufacturer Boehringer Ingelheim says.

Health Minister Tanya Plibersek has this week flagged that Bayer's rivaroxaban (Xarelto) will "soon be subsidised" as a treatment for the prevention of stroke in patients with atrial fibrillation.